Researchers at Stanford have developed a nucleic acid amplification test to detect high-risk Epstein-Barr Virus (EBV) BALF2 variants in plasma to aid population-level screening for nasopharyngeal carcinoma (NPC).
Stanford University researchers have developed aptamer-antibody chimeras that achieve dynamic, sensitive, and specific biomolecule sensing beyond the capacity of antibodies or aptamers alone.